Tag ~immunotherapy

Tag descriptions coming soon to Wherrelz News!

Biotech startup Kineta inks cancer deal with Pfizer worth up to 505M

BristolMyers Squibbs 74B acquisition of Juno parent Celgene puts Seattle biotech world on alert

Cell therapies are giving Seattle an edge in biotech driving three acquisitions in under a month

Seattle Genetics to acquire Cascadian Therapeutics for 614M to further bolster its cancer fight

The convergence of deep neural networks and immunotherapy

Portland immunotherapy startup tops 10M in funding as it launches first clinical trial

CAR TCell Immunotherapy Market Competitive Landscape Trends Market Concentration Rate Business Strategies 2023

Juno finds clinical success with cancer drug beats analyst expectations with 44M in revenue

OncoResponse raises 40M to start clinical trials of antibodybased cancer immunotherapies

Sonoma Biotherapeutics raises 265M to advance therapies for autoimmune inflammatory diseases

Immunai wants to map the entire immune system and raised 20 million in seed funding to do it

Fred Hutch study: Nanoparticles could help cuttingedge therapies get inside solid tumors

Startup Aminex Therapeutics raises 10M begins clinical trials of immunotherapy treatment

Juno Therapeutics stock surges 50 as Celgene is reportedly in talks to buy the company

How this cancer therapy went from scientific underdog to potential cure

Seattle Genetics COO taking the reins at stealthy biotech startup Silverback Therapeutics

Inside Seattle Childrens landmark 1B campaign to cure childhood cancer and other diseases

Thin metal films loaded with immune cells show promise as cancer therapy

Celgene CEO: Treating cancer is becoming ironically easy now the problem is affordability

Why Celgene decided to buy Juno Therapeutics for 9B with a little help from US tax reform

Drug giant Merck pays 300M to acquire Seattle biotech company Immune Design

Longtime Juno Therapeutics CEO Hans Bishop leaves role after merger with Celgene

Longtime Juno Therapeutics CEO Hans Bishop leaves role after acquisition by Celgene

Merck research chief Roger Perlmutter touts Seattle biotech strength after 300M Immune Design deal